Medication10 minute read
How GLP-1 weight-loss medication works: a plain-language guide
What GLP-1 and dual GIP/GLP-1 medicines do in the body, who doctors usually consider them for, what the large trials measured and why they are treated as long-term care.

DIRECT ANSWER
An online consultation lets an EU-licensed doctor review your case and, if appropriate, issue a prescription that is valid across the EU.
Doctor reply in under 2 hours
Average doctor reply under 2 hours; prescription within 24 hours if approved.
EU-licensed doctors
Every case is reviewed by a licensed clinician.
Valid across the EU
Approved prescriptions can be used at any EU pharmacy.
HOW IT WORKS
From consultation to collection
- 1
Consultation
Answer a secure medical questionnaire online.
- 2
Doctor reviews
An EU-licensed doctor personally assesses your case.
- 3
Prescription in less than 2 hours on average
If approved, your prescription is issued in less than 2 hours on average.
- 4
Collect at any EU pharmacy
Use an approved prescription at a pharmacy anywhere in the EU.
Key takeaways - GLP-1-based medicines copy a gut hormone that tells the brain you have eaten, so hunger falls and fullness comes sooner. - In large trials, average weight loss was around 15% to 21% over 68 to 72 weeks (about 16 months), alongside diet and activity advice, with wide individual differences. - They are usually considered for adults with a BMI of 30 or more, or a lower BMI with a weight-related health condition, and only after a doctor's assessment. - Stomach and bowel side effects are common, especially when the dose goes up, and usually ease with time. - These medicines work while they are taken. On average, people regain much of the lost weight after stopping, so they are treated as long-term care.
Docalo pairs you with a licensed doctor who reviews your health and builds a weight plan with you.
You may have heard a lot about GLP-1 medicines lately, from friends, news stories or social media. Some of it is accurate, some is not, and it can be hard to tell which is which.
This guide explains, in plain language, what these medicines do in the body, who doctors usually consider them for, what the large trials actually measured and what the common side effects are. It is general education, not a recommendation: whether any medicine is right for you is a decision for a doctor who knows your health.
What is GLP-1, and what do these medicines copy?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It is one of several signals that tell your brain food has arrived. Natural GLP-1 only lasts a few minutes in the blood before it is broken down.
GLP-1-based medicines are built to act like this hormone but to last much longer, so the signal stays on for days rather than minutes. Some are taken once a week as an injection, others daily. A newer group, dual GIP/GLP-1 medicines, also copies a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide), which works alongside GLP-1 on appetite and blood sugar.
What these medicines do in the body
The effects are spread across several organs. The table gives a simplified picture.
| Where | What happens | What you may notice |
|---|---|---|
| Brain (appetite centres) | Hunger signals are turned down and fullness signals turned up | Smaller portions feel enough, fewer cravings, less "food noise" |
| Stomach | Food leaves the stomach more slowly, especially at first | Feeling full for longer, sometimes nausea or early fullness |
| Pancreas | More insulin is released when blood sugar is high, less glucagon | Steadier blood sugar after meals |
| Reward pathways | Food may feel less rewarding for some people | Less pull towards very rich or sweet foods |
The main reason weight falls is simple: people eat less because they feel less hungry. The medicine does not "melt fat" or speed up metabolism. That is why the quality of what you eat, especially protein, still matters a great deal.
Who are they usually considered for?
In the main obesity trials, participants were adults with a body mass index (BMI) of 30 or more, or 27 or more with at least one weight-related health problem such as high blood pressure, raised cholesterol or sleep apnoea. Licensing in Europe follows similar lines. You can check your BMI with the BMI calculator, keeping in mind that BMI is only a starting point.
Guidelines add more detail. The NICE guideline on overweight and obesity says medicines should be used alongside a reduced-calorie diet and more physical activity, not instead of them. The NICE appraisals for a weekly GLP-1 medicine and a dual GIP/GLP-1 medicine set stricter criteria for NHS funding in England, generally focusing on people with a higher BMI and at least one weight-related condition, with lower BMI thresholds for some ethnic backgrounds where health risks rise at lower weights. Rules differ between countries and change over time.
Medication is not suitable for everyone. A doctor will usually ask about:
- Pregnancy, breastfeeding or plans to conceive. These medicines are not used in pregnancy.
- Past pancreatitis or gallbladder problems. These need careful discussion.
- Other medicines. Some interact, and the doctor will also ask about contraception.
- Eating disorders. A history of restrictive eating needs a different conversation.
- Your goals and expectations. Medication is one tool, not the whole plan.
If clinically appropriate, a doctor may prescribe a GLP-1-based medicine as part of a wider plan. If not, there are other options worth discussing.
What the major trials measured
The evidence comes mainly from three large, placebo-controlled trials. In STEP 1 and SURMOUNT-1, all participants also received advice on diet and physical activity.
| Trial | Who took part | Length | Average result |
|---|---|---|---|
| STEP 1 | 1,961 adults with overweight or obesity, without diabetes | 68 weeks | Weight fell by 14.9% on a weekly GLP-1 medicine vs 2.4% on placebo |
| SURMOUNT-1 | 2,539 adults with overweight or obesity, without diabetes | 72 weeks | Weight fell by 15.0% to 20.9% on a dual GIP/GLP-1 medicine (by dose) vs 3.1% on placebo |
| SELECT | 17,604 adults with overweight or obesity and existing heart disease, without diabetes | Around 3 years on average | Major heart events (heart attack, stroke, cardiovascular death) in 6.5% vs 8.0% on placebo |
How to read these numbers
- They are averages. In every trial, some people lost much more and some lost little. A minority did not respond in a meaningful way.
- Trial conditions are not daily life. Participants had regular visits and structured support, which may not match real-world care.
- SELECT measured something different. It looked at heart events in people who already had heart disease. That is a 20% relative reduction, which is important, but it does not mean everyone taking a GLP-1 medicine will have the same benefit.
- Long-term data are still growing. Most trials ran for one to three years. Doctors keep following people on treatment for this reason.
Common side effects
Most side effects affect the stomach and bowel: nausea, diarrhoea, constipation, vomiting, reflux and bloating. In the trials they were usually mild to moderate, most frequent when the dose was being increased, and tended to fade over the following weeks. A practical review of side-effect management recommends starting low, increasing the dose slowly and adjusting how you eat.
That is why treatment normally starts at a low dose and steps up every few weeks. Our guide to nausea and digestive side effects covers practical tips and the symptoms that need urgent care, such as severe, persistent tummy pain. Our guide to eating well on GLP-1 treatment explains how to get enough nourishment when your appetite is low.
Why lifestyle support still matters
Medication changes how hungry you feel, but it does not choose your food or move your body. Lifestyle support helps in three ways:
- Protecting muscle. Some of the weight lost on any treatment is lean tissue. Enough protein and regular strength training help limit this. See our guide to protecting muscle during weight loss.
- Feeling well on treatment. Smaller meals, enough fluid and fibre reduce side effects.
- Building habits that last. Routines formed while appetite is quieter make maintenance easier later.
Why these are long-term treatments
Obesity is a long-term condition. When weight falls, the body raises hunger and lowers energy use to try to regain it. GLP-1-based medicines counter that push while they are being taken, and the effect fades after they stop.
In randomised trials that switched some participants to a placebo, and in a trial extension that followed people after they stopped both the medicine and a lifestyle programme, a large share of the lost weight came back on average within a year. Our article on weight regain after stopping treatment explains those results and how to plan with your doctor. For many people this means treatment is reviewed regularly and continued for as long as the benefits outweigh the downsides, much like medicine for blood pressure.
How Docalo can help
Docalo is an online medical service focused only on weight loss. Your €49/month membership covers a doctor consultation, a personal plan and follow-up with the medical team, so questions about medication are answered by a doctor who knows your history.
A licensed doctor reviews your health questionnaire and decides whether treatment is appropriate for you. That may or may not include medication. If a doctor prescribes it, it is paid separately at the pharmacy. If you would like to understand your options, you can start your consultation.
One Docalo membership covers the doctor assessment, a personal plan, monthly follow-up and messaging. Medication, if prescribed, is paid separately at the pharmacy.
COMMON QUESTIONS
Frequently asked questions
No. They work mainly by reducing hunger and helping you feel full sooner, so you naturally eat less. Weight falls because energy intake drops. They do not raise your metabolism or target fat directly, which is why protein, strength training and the overall quality of your diet still matter while you are on treatment.
References
- Wilding JPH et al. The STEP 1 trial. N Engl J Med 2021;384:989-1002.
- Jastreboff AM et al. The SURMOUNT-1 trial. N Engl J Med 2022;387:205-16.
- Lincoff AM et al. The SELECT trial. N Engl J Med 2023;389:2221-32.
- NICE guideline NG246: Overweight and obesity management. 2025.
- NICE technology appraisal TA875: weekly GLP-1 medicine for managing overweight and obesity.
- NICE technology appraisal TA1026: dual GIP/GLP-1 medicine for managing overweight and obesity.
- Wharton S et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity. Postgrad Med 2022;134:14-19.





